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Abstract
Background: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell
types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the
potential diagnostic value of serum CD26 levels in gastric cancer.
Methods: Soluble serum CD26 levels were measured in pre and postoperative serum samples of 30 patients with
gastric cancer and in 24 healthy donors by a specific ELISA kit.
Results: We found significantly lower serum CD26 levels in patients with gastric cancer (557.7 ± 118.3 pg/mL)
compared with healthy donors (703.4 ± 170.3 pg/mL). Moreover patients with HER2 positive tumors had significantly
lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006).
A binary logistic model having gastric cancer as the dependent variable while age, gender, CEA, CA19.9 and
CD26 levels as covariates, showed that CD26 serum levels were independently associated with gastric cancer
presence. Indeed after 3 months from surgery serum CD26 levels significantly increased (700.1 ± 119.9 pg/mL vs
557.7 ± 118.3 pg/ml) in all patients (t = −4.454, p < 0.0001).
Conclusions: This is a preliminary study showing that the measurement of serum CD26 levels could represent an
early detection marker for gastric cancer.
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Background
Gastric cancer, despite its decreasing incidence, repre-
sents one of the major health problem worldwide and
the fifth most common type of cancer [1]. Gastric cancer
is a silent disease frequently diagnosed in advanced
stages, which is responsible for its elevated mortality es-
pecially among the elderly population where the
incidence is significantly higher [2, 3]. Advances in tech-
nology have allowed the development of several methods
to understand the mechanisms underlying gastric car-
cinogenesis, resulting in the identification of a large
number of molecular targets that can be used as bio-
markers with diagnostic and prognostic potentials.
Recent studies have identified CD26/ dipeptidyl peptid-
ase 4 (DPP4) as a gene that affects the invasiveness of
many tumor cells [4–8] and it is consistently associated
with cancer. CD26/dipeptidyl peptidase 4 is a widely
expressed cell surface peptidase that exhibits a complex
biology with three different functions: adenosine deami-
nase (ADA) binding, serine peptidase activity, and extra-
cellular matrix (ECM) binding. CD26 may be cell
membrane-anchored or in a soluble form, occurring in
the serum (sCD26). Cell-associated CD26 is widely
expressed on T cells, B cells, natural killer cells, endothe-
lial cells and epithelial cells. The different biological ac-
tivities of CD26 and its ubiquitous expression may
reflect its diverse, sometimes opposing functions in
physiological and pathological settings [9].
A deficiency in solubilized CD26 was reported in total
homogenates of tumors of colon, kidney, lung and liver.
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On the contrary, cell-surface CD26 expression has been
correlated with disease aggressiveness of T and B cell
lymphomas and leukaemias, follicular cell-derived thy-
roid carcinomas and basal cell carcinomas [10]. In
addition, serum DPP4 levels is increased in patients with
hepatic cancer and decreased in patients with blood,
solid and oral cancer [10, 11]. Recently, CD26 has been
identified as a serum marker for colorectal cancer detec-
tion [11–13] as well as a prognostic factor able to pro-
mote human colorectal cancer metastasis [14], while to
best of our knowledge no study investigated the role of
serum CD26 in gastric cancer. Only a previous study
suggested that CD26 expression level in surgical samples
may be considered a reliable biomarker of malignant
GISTs of the stomach characterized by distinct clinical,
genetic, and histopathological features [15]. Considering
that non-invasive biological serum markers would be of
great benefit for screening, we aimed at investigating the
potential role of CD26 serum levels as a diagnostic
marker for gastric cancer detection.
Patients and methods
Patients
Preoperative blood samples were collected between
January 2013 and October 2014 from 30 patients with
histologically documented gastric adenocarcinoma who
were candidates for surgical treatment either with cura-
tive or palliative intent. Exclusion criteria were previous
abdominal radiotherapy, preoperative chemotherapy,
diabetes, history of recent immunosuppressive therapy
or immunological and hematologic disorders, ongoing
infection.
Tumor location, size, Lauren’s type, degree of differen-
tiation, pTNM as well as stage according to the 7th edi-
tion of the American Joint Committee on Cancer
(AJCC)/Union for International Cancer Control (UICC)
tumor, node, metastasis (TNM) staging system [16],
oncological radicality of resection and HER2 has been
examined.
The control group consisted of 24 healthy blood do-
nors. To avoid bias individuals with evidence of acute
inflammatory or infectious diseases, diabetes, immuno-
logic or hematologic disorders have been ruled out. Clin-
ical information was obtained by routine laboratory
analyses, history and physical examination. After a clear
explanation of the potential risks of the study, all sub-
jects provided written informed consent to participate in
the study, which was approved by the ethical committee
of the Second University of Naples.
Analytical methods
Blood samples were collected in the morning after the
participants had been fasting for at least 8 h. The drawn
blood was allowed to coagulate at room temperature
and centrifuged at 2000 g for 15 min. The sera were
stored at −85 °C until used.
Determination of CD26 serum levels
The concentration of serum CD26 were analyzed using
a specific immunoassays (Human CD26/DPP4 ELISA
Kit, Boster biological technology, Pleasanton, CA) ELI-
SAs were performed according to the manufacturer’s in-
structions: mean values of duplicated measurements
were calculated and a sigmoid-shaped standard curve
was determined by simultaneously analyzing a dilution
series of standard samples.
Determination of CEA and CA19.9 serum levels
CEA and CA19.9 levels were analyzed in serum by spe-
cific ELISA kits according to manufacturer’s instructions.
The cut-off were < 5 ng/ml for CEA and <37 U/ml for
CA19.9.
Determination of HER2 expression in cancer tissues
HER-2 status was tested by immunohistochemistry
(IHC) on all tumor samples of evaluated patients while in
equivocal (2+) samples fluorescence in situ hybridization
(FISH) was performed. Tumor samples immune-stained
on 3‑μm thick sections that were mounted on sila-
ne‑coated slides using HercepTest™ (Dako, Glostrup,
Denmark). Each immune-stained section was evaluated ac-
cording to ToGA trial criteria: no reactivity or membran-
ous reactivity < 10 % of tumor cells (0+, negative); faint
incomplete membranous reactivity in ≥ 10 % of tumor cells
(1+, negative); weak to moderate complete basolateral or
lateral membranous reactivity in ≥ 10 % of tumor cells (2+,
equivocal); strong complete basolateral or lateral mem-
branous reactivity in ≥ 10 % of tumor cells (3+, positive).
The FISH test (pharmDx; Dako, Glostrup, Denmark) was
performed in all cases of equivocal results (IHC 2+). Gene
amplification was recorded when the HER2 and centro-
mere probe 17 (CEP17) signal ratio was >2.0.The HAC
samples were tested using polyclonal rabbit anti-human α-
1-fetoprotein (clone A000802-29) and monoclonal mouse
anti-human hepatocyte (Clone OCH1E5) (Dako, Glostrup,
Denmark). Tumors were classified as negative when the
HER2:CEP17 ratio was < 1.8 and positive when the HER2:-
CEP17 ratio was ≥ 2.2. If the HER2:CEP17 ratio was ≥ 1.8
but < 2.2 the specimen was considered equivocal.
Calculations and statistical analyses
The observed data are normally distributed (Shapiro-Wilk
W-Test) and presented as means ± Standard Deviation
(SD). The analyses were performed with Chi-square,
paired t test or unpaired t test where appropriated. A cut
off value for CD26 was determined using receiver operat-
ing characteristics (ROC). Sample size calculation was es-
timated on an IBM PC computer by GPOWER software.
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The resulting total sample size, estimated according to a
global effect size of 25 % with type I error of 0.05 and a
power of 80 % was 57 cases. All p values presented are 2-
tailed and a p ≤ 0.05 was chosen for levels of significance.
Statistical analyses were performed using SPSS 17 soft-
ware package (SPSS, Inc., Chicago, IL).
Results
CD26 levels in serum of patients with gastric cancer and
healthy donors
The serum CD26 levels were measured in 24 healthy
subjects (14 men and 10 women) with a median age of
63.5 ± 11.1 years. The study group included 30 patients
with gastric cancer (16 men and 14 women) with a me-
dian age of 66.9 ± 10.2 years. The two groups did not dif-
fer in age (p = 0.262) and gender (χ2 = 0.053, p = 0.519).
The mean serum level of CD26 in patients with gastric
cancer was 557.7 ± 118.3 pg/mL, significantly lower than
that in healthy individuals (703.4 ± 170.3 pg/mL, P =
0.001) (Fig. 1). No difference in CD26 levels were found
among gender (p = 0.392) in all population study. No
correlation was found between CD26 serum levels and
age (r = −0.178, p = 0.232).
Serum CD26 levels and clinicomorphologic tumors
characteristics
Table 1 provides clinicopathologic data for all patients
with gastric cancer (n = 30). The relationships between
serum CD26 levels and tumor location, size, Lauren’s
type, degree of differentiation, pTNM, stage, oncological
radicality of resection and HER2 expression were exam-
ined (Table 1). No differences in serum CD26 levels
were found among all variable described except for
HER2 expression: patients with HER2 positive tumors
had significantly lower CD26 serum levels (511.8 ±
84.8 pg/mL) compared HER2 negative tumors (619.1 ±
109.9 pg/mL, p = 0.006). Patients with positive lymph
node metastasis had lower CD26 levels, however such a
difference did not reach the statistical significance. Re-
garding other preoperative markers, CEA and CA19.9
were determined in all patients. A positive correlation
between CEA and CA19.9 levels were found (r = 0.515,
p = 0.004). The cut off were determined for both markers
according to previous literature: 7 (23.3 %) (χ2 = 0.900, p =
0.279) patients resulted over the cut-off for CA19.9 and 4
(12 %) (χ2 = 0.279, p = 0.471) patients resulted over the
cut-off for CEA. The clinical and morphologic tumors
characteristics were also studied according to the positive
for each of these clinical markers (data not shown) and
only HER2 positive tumors were associated with a positive
value for CEA (χ2 = 4.971, p = 0.042). No significant cor-
relation between CD26 and other studied markers were
found.
Diagnostic efficiency of CD26 preoperative serum levels
A binary logistic model having gastric cancer as the
dependent variable while age, gender, CEA, CA19.9 and
CD26 levels as independent variables, showed that CD26
serum levels were independently associated with gastric
cancer presence (Table 2). ROC curve for CD26 showed
an area under the curve of C = 0.738 with SE = 0.071 and
95 % CI from 0.598–0.877 (Fig. 2). The best cut-off that
maximizes (sensitivity + specificity) was 465.8 pg/mL. At
this level, the sensitivity was 0.90 and specificity was
0.43. At this established cut off level 8 (26.6 %) patients
resulted behind the cut-off (χ2 = 7.224, p = 0.007) show-
ing higher diagnostic efficiency compared CEA and
CA19.9. After 3 months from surgery CD26 levels sig-
nificantly increased (700.1 ± 119.9 pg/mL vs 557.7 ±
118.3 pg/mL) in all patients (t = −4.454, p < 0.0001).
Discussion
The major findings of our investigation are: i) patients
affected by gastric cancer have significantly lower serum
CD26 levels compared with healthy subjects ii) CD26
serum levels are associated with gastric cancer presence
iii) CD26 measurement shows higher diagnostic effi-
ciency compared CEA and CA19.9 in gastric cancer iiii)
patients with HER2 positive tumors have significantly
lower serum CD26 levels compared with the HER2
negative counterpart.
Gastric cancer represents the third most common
cause of cancer-related death in the world and most pa-
tients present advanced disease at diagnosis making its
treatment very intricate [1–3]. It is widely accepted that
early diagnosis and treatment are keys for better clinical
outcome in patients with gastric cancer [2, 3].
CD26 is a multifunctional cell surface glycoprotein
with intrinsic dipeptidyl peptidase 4 activity particularly
expressed on epithelial cells and lymphocytes [9, 17, 18].
However, CD26 also exists as a soluble circulating form
Fig. 1 CD26 serum levels in patients with gastric cancer (n = 30) and
in control healthy individuals (n = 24). Patients serum CD26 levels:
557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/
mL. *p = 0.001 by unpaired t test
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in plasma and its role it is still unknown. Cell surface
proteases participate in malignant transformation and
cancer progression by promoting invasion and metasta-
sis. Sometimes they can also gave an opposite effect, this
is the case of CD26 [11, 17]. In fact, surface CD26 ex-
pression is lost or altered in melanoma, hepatocellular
carcinoma and colon cancer cells [10]. It has been sug-
gested that CD26 with its enzymatic activity is able to
degrade growth factors required for survival and inva-
siveness of tumor cells [12]. Also serum CD26 is sub-
stantially dysregulated in various cancers: serum CD26
levels are increased in patients with hepatic cancer and
decreased in patients with blood, thyroid and oral can-
cers [10, 11]. Recently, CD26 has been identified as a
serum marker for colorectal cancer detection and prog-
nostic factor [12–14] while to best of our knowledge no
study investigated the role of serum CD26 in presence of
gastric cancer.
With this preliminary study we found that patients af-
fected by gastric cancer have lower levels of circulating
serum CD26 compared with healthy controls, thus
representing a powerful biomarkers of gastric cancer.
We found a lack of any association of sCD26 levels with
tumor localization, size, type, differentiation, TNM, stage
or lymph node metastases. Accordingly Cordero and
colleagues [12, 13] did not found any relationship be-
tween the levels of sCD26 and the Dukes’ stage classifi-
cation in patients affected by colorectal cancer. These
data collectively suggest the potential usefulness of this
molecule for early diagnosis of gastric cancer. The re-
gression analysis showed that lower sCD26 levels were
associated to gastric cancer presence independent of age,
gender and others tumors biomarkers (CA19.9 and
CEA). This findings further support the relevance of
CD26 as a new diagnostic marker for gastric cancer with
higher efficiency compared with other available bio-
markers as shown by the ROC curve. Whether lower
CD26 serum levels are associated with lower or higher
tumor surface expression is unknown and may represent
a limitation of this study. However, previous evidence
are showing that impairment in sCD26 in colorectal can-
cer does not seem to be originated by alteration of
CD26 on tumour cells [11–13]. Thus, we can speculate
Table 1 Clinicopathologic data for all patients with gastric




Tumor location n (%)
Upper 6 (20 %) 556.1 ± 77.2 0.986
Middle 11 (36.6 %) 558.0 ± 133.8
Lower 13 (43.4 %) 564.2 ± 108.5
Tumor size n (%)
<3 cm 15 (50 %) 569.1 ± 101.2 0.800
>3 cm 15 (50 %) 558.5 ± 121.6
Lauren’s Type n (%)
Intestinal 20 (60 %) 564.8 ± 94.8 0.934
Diffuse 10 (40 %) 651.0 ± 145.9
Differentation n (%)
well 4 (13.3 %) 556.3 ± 95.4 0.681
moderately 20 (66.7 %) 553.9 ± 120.0
poorly 6 (20 %) 559.8 ± 107.2
Tumor status n (%)
T1a 0 - 0.781
T1b 2 (6.6 %) 556.3 ± 0
T2 6 (20 %) 563.4 ± 88.1
T3 12 (40 %) 543.5 ± 146.9
T4a 7 (23.3 %) 636.7 ± 0
T4b 3 (10 %) 579.6 ± 88.9
Lymph node metastasis n (%)
N0 12 (40 %) 602.8 ± 120.1 0.113
N1 8 (40 %) 511.3 ± 50.6
N2 4(6.6 %) 447.7 ± 109.2
N3a 2 (10 %) 660.2 ± 0
N3b 4 (3.4 %) 636.7 ± 0
Metastatic disease n (%)
M0 26 (86.7 %) 562.0 ± 114.7 0.660
M1 4 (13.3 %) 586.2 ± 83.5
Stage n (%)
Ia 1 (3.4 %) 546.1 ± 26.5 0.513
Ib 4 (13.3 %) 587.2 ± 81.3
IIa 2 (6.6 %) 603.3 ± 144.3
IIb 1 (3.4 %) 626.8 ± 101.8
IIIa 8 (26.6 %) 587.1 ± 59.7
IIIb 5 (16.7 %) 613.8 ± 150.4
IIIc 5 (16.7 %) 564.8 ± 119.7
IV 4 (13.3 %) 518.9 ± 70.4
Table 1 Clinicopathologic data for all patients with gastric
cancer (n = 30) (Continued)
Resection type n (%)
R0 25 (83.3 %) 562.0 ± 114.7 0.660
R1-2 5 (16.7 %) 586.2 ± 83.5
HER2 n (%)
positive 15 (50 %) 511.8 ± 84.8 0.006
negative 15 (50 %) 619.1 ± 109.9
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that the drop in serum CD26 levels may be related to a
dysfunction in the immune system status in patients
with gastric cancer. In fact, a cross-talk between the
lymphoid lineage and malignant tumors in vivo have
been long discussed and some data about the immune
defective antitumor response in many cancers, such as
colonic, have been described before, including a defect
in IL-12 production [19], which is a well-known CD26
up-regulator on T cells [20]. Again in oral cancer pa-
tients, in which around a 50 % decrease in serum CD26
activity has been reported, a correlation between sCD26
and CD26+ T was found, and the mount of CD26 in T
lymphocyte plasma membranes were significantly lower
than in healthy subjects [21]. Thus, even in the gastric
cancer, the hypothetic role of sCD26 in crosstalk be-
tween the immune system and carcinogenesis, cannot be
ruled out. Further studied are needed to test such an hy-
pothesis and to collect the lymphocyte count, subset dis-
tribution and other immune parameters in patients with
gastric cancer. Interestingly recent studies are showing
that sCD26 therapy enhances the immune function in
some pathological conditions such as AIDS [22] and it
might be interesting to analyze if gastric cancer patients
may well benefit from exogenous sCD26 treatment.
Our most important finding is that lower serum CD26
levels were found particularly in sera of patients with
HER2 positive tumors. Upon the increased knowledge of
breast cancer cells molecular pathways, the biological
feature of gastric cancer is becoming more clear and
particular attention should be paid to the identification
of the human epidermal growth factor receptor-2
(HER2) amplified gastric cancer subtype. This latter ac-
counts for 10–38 % of all gastric cancers, with an higher
prevalence in tumors from the upper third of the stom-
ach than in those located in more distal areas, as well as
in Lauren’s intestinal type than in diffuse-type gastric
cancer [23]. HER2 protein overexpression on the gastric
cancer cells’ surface with its enhanced and prolonged
signals influence particularly the carcinogenesis processes
determining distinctive clinic-pathological phenotype
characterized by acquisition of advantageous properties
for excessive and uncontrolled cell growth, identifying a
distinctive gastric cancer entity [24]. From a prognostic
perspective, even though the negative prognostic effect of
HER2 positivity in breast cancer is well assessed, the rela-
tionship between HER2 status and prognosis of gastric
cancer patients remains controversial [25]. Nevertheless
the administration of standard chemotherapy with
Trastuzumab, a monoclonal antibody that binds to the
extracellular domain of the HER2 receptor blocking its
downstream signaling, shows a clinically meaningful
improvement in overall survival for patients with HER2-
positive advanced gastric cancer [26]. The lower serum
CD26 levels in patients with HER2 positive tumors sug-
gests an attractive linking mechanism between innate ef-
fector cells/T-cells immunity and the anti-tumoral effects.
Supporting this, it has been demonstrated that CD26 is a
potential target for amino boronic dipeptide PT-100, a
dipeptidyl peptidase (DPP) inhibitor, which is able to
augment the effect of trastuzumab on the growth in-
hibition of HER2 positive carcinoma cell lines in ani-
mal models [27].
Indeed, establishing the diagnosis at an early stage in gas-
tric cancer, with a simple biochemical index, is a current
subject of research in clinical oncology. The CEA levels are
the marker of reference in this neoplasia, although not rec-
ommended as diagnostic test [28]. Our results revealed
that sensitivities of sCD26 were higher at different specifi-
city levels than those of CEA or CA 19.9 as well as effi-
ciency. Indeed, the fact the CD26 levels significantly
increase after surgery may indicate that the sCD26 serum
level may be used also as prognostic marker. However fur-
ther studies are needed to validate such an hypothesis.
Table 2 Binary logistic regression analysis with gastric cancer as
the dependent variables in all population study (n = 54)
B Odds Ratio 95 % CI p
Gender −0.188 0.828 0.220–3.123 .828
Age 0.019 1.019 0.957–1.086 .551
CD 26 −0.007 0.993 0.988–0.998 .003
CEA 0.837 2.308 0.255–20.928 .457
CA19.9 0.507 1.660 0.277–9.963 .579
Gender expressed as F = 0 an M = 1
Fig. 2 ROC curve for sCD26. ROC curve for sCD26 showed an area
under the curve of C = 0.738 with SE = 0.071 and 95 % CI from
0.598–0.877. The best cut-off that maximizes (sensitivity + specificity)
was 465.8 pg/mL
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Conclusions
Using novel biomarkers to early gastric cancer detection
may potentially decrease mortality and medical costs.
Preoperative sCD26 level may represent an useful and
easy biomarker for early detection of gastric cancer. In-
deed the finding that patients with HER2 positive
tumors have lower sCD26 levels may have clinical po-
tential in gastric cancer management improving the ef-
fect of drugs on the growth inhibition of HER2 positive
cancers.
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